<CTGovProtocol id="CDR0000363917">
  <RequiredHeader>
    <DownloadDate>Information obtained from ClinicalTrials.gov on 2005-12-09</DownloadDate>
    <LinkText xref="http://clinicaltrials.gov/show/NCT00080015">Link to the current ClinicalTrials.gov record.</LinkText>
  </RequiredHeader>
  <IDInfo>
    <OrgStudyID>Ipsen Protocol 2-91-52990-708</OrgStudyID>
    <NCTID>NCT00080015</NCTID>
  </IDInfo>
  <BriefTitle>Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)</BriefTitle>
  <Sponsors>
    <PDQSponsorship>Pharmaceutical/Industry</PDQSponsorship>
    <LeadSponsor ref="CDR0000453373">Beaufour Ipsen International SNC</LeadSponsor>
    <OverallOfficial>
      <GivenName>Thierry</GivenName>
      <MiddleInitial>Le</MiddleInitial>
      <SurName>Chevalier</SurName>
      <ProfessionalSuffix>MD</ProfessionalSuffix>
      <Role>Principal Investigator</Role>
      <Affiliation>Institut Gustave Roussy, Villejuif, Paris, France</Affiliation>
    </OverallOfficial>
  </Sponsors>
  <BriefSummary>
    <Para>This is a Phase II, open-label, multicenter, single-arm, exploratory “proof of concept” study. Diflomotecan (7 mg fixed dose) will be administered as a 20-minute IV infusion once every 3 weeks in patients with sensitive small cell lung cancer (SCLC) with progressive disease after first-line treatment with a platinum-based regimen.</Para>
</BriefSummary>
  <CTEntryCriteria>
    <Para>Main Inclusion Criteria:</Para>
    <ItemizedList Style="bullet">
      <ListItem>Documented small cell lung cancer (SCLC)</ListItem>
    </ItemizedList>
    <ItemizedList Style="bullet">
      <ListItem>Measurable disease</ListItem>
    </ItemizedList>
    <ItemizedList Style="bullet">
      <ListItem>One line of previous chemotherapy, including any platinum analogue, and excluding any camptothecin analogues, with objective response and relapsed no less than 3 months</ListItem>
    </ItemizedList>
    <Para>Main Exclusion Criteria:</Para>
    <ItemizedList Style="bullet">
      <ListItem>Uncontrollable brain metastasis</ListItem>
    </ItemizedList>
    <ItemizedList Style="bullet">
      <ListItem>Treated with an investigational drug within 30 days</ListItem>
    </ItemizedList>
  </CTEntryCriteria>
  <CTGovDisclaimer>Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain 
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.</CTGovDisclaimer>
  <CurrentProtocolStatus>Closed</CurrentProtocolStatus>
  <ProtocolPhase>Phase II</ProtocolPhase>
  <ProtocolDetail>
    <StudyType>Clinical trial</StudyType>
    <StudyCategory>
      <StudyCategoryName>Treatment</StudyCategoryName>
      <Intervention>
        <InterventionType ref="CDR0000039455">chemotherapy</InterventionType>
        <InterventionNameLink ref="CDR0000372902">diflomotecan</InterventionNameLink>
      </Intervention>
    </StudyCategory>
  </ProtocolDetail>
  <Eligibility>
    <HealthyVolunteers>No</HealthyVolunteers>
    <LowAge>18</LowAge>
    <HighAge>120</HighAge>
    <AgeText>18 and over</AgeText>
    <Diagnosis>
      <SpecificDiagnosis ref="CDR0000037831">recurrent small cell lung cancer</SpecificDiagnosis>
      <DiagnosisParent ref="CDR0000040962">small cell lung cancer</DiagnosisParent>
      <DiagnosisParent ref="CDR0000040209">lung cancer</DiagnosisParent>
      <DiagnosisParent ref="CDR0000039286">thorax/respiratory cancer</DiagnosisParent>
      <DiagnosisParent ref="CDR0000043666">body system/site cancer</DiagnosisParent>
      <DiagnosisParent ref="CDR0000041060">cancer</DiagnosisParent>
      <DiagnosisParent ref="CDR0000040460">adult solid tumor</DiagnosisParent>
      <DiagnosisParent ref="CDR0000040461">solid tumor</DiagnosisParent>
    </Diagnosis>
  </Eligibility>
  <VerificationDate>August 2005</VerificationDate>
  <LastChangedDate>December 8, 2005</LastChangedDate>
</CTGovProtocol>